Cargando…
The Effect of Discontinuing Denosumab in Patients With Rheumatoid Arthritis Treated With Glucocorticoids
OBJECTIVE: To evaluate changes in bone turnover and bone mineral density (BMD) in patients with rheumatoid arthritis (RA) receiving glucocorticoids, after discontinuation of denosumab for 12 months. METHODS: We conducted a randomized, double‐blind, placebo‐controlled, phase II study of RA patients....
Autores principales: | Saag, Kenneth G., McDermott, Michele T., Adachi, Jonathan, Lems, Willem, Lane, Nancy E., Geusens, Piet, Stad, Robert Kees, Chen, Li, Huang, Shuang, Dore, Robin, Cohen, Stanley |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wiley Periodicals, Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305881/ https://www.ncbi.nlm.nih.gov/pubmed/34535967 http://dx.doi.org/10.1002/art.41981 |
Ejemplares similares
-
Individual patient data meta-analysis on continued use of glucocorticoids after their initiation as bridging therapy in patients with rheumatoid arthritis
por: van Ouwerkerk, Lotte, et al.
Publicado: (2023) -
Glucocorticoids and chronotherapy in rheumatoid arthritis
por: Cutolo, Maurizio
Publicado: (2016) -
Glucocorticoids in rheumatoid arthritis: current status and future studies
por: Hua, Charlotte, et al.
Publicado: (2020) -
Risk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis
por: Riley, Thomas R, et al.
Publicado: (2021) -
Identifying the preferable rheumatoid arthritis subgroups for intervention with the anti-RANKL antibody denosumab to reduce progression of joint destruction
por: Tanaka, Yoshiya, et al.
Publicado: (2020)